Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
The FDA has given the nod to the Chinese company’s PD-1 drug, but most of the benefits will go to a third-party licensee Key Takeaways: Junshi Bio will receive milestone…
1877.HK
688180.SHG
FAST NEWS: Beigene stock falls after Novartis terminates partnership
The latest: Cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Tuesday that Novartis (NOVN.SWX) will relinquish its rights to co-develop, produce and commercialize BeiGene’s esophagus cancer drug tislelizumab. Looking up: Novartis will provide…
BGNE.US
6160.HK
Sales success comes with side effects for drug maker BeiGene
The Chinese biotech’s product revenues surged nearly 82% in the second quarter, driven by forecast-beating sales of its core cancer drugs Key Takeaways: Global sales of BeiGene's anti-tumor drug zanubrutinib…
BGNE.US
6160.HK
Daylight ahead for China’s battered semiconductor sector?
Interim results from Chinese semiconductor companies suggest change for the better lies ahead for this group By Research-Select Major Chinese microchip maker Hua Hong Semiconductor Ltd. (1347.HK; 688347.SH) went…
1347.HK
Henlius finds elixir in first profits, scraps A-share IPO
The drug maker said last week it will halt plans for a second listing on China’s STAR Market, the same day it announced its first-ever interim profit since its 2019…
2696.HK
PODCAST: Corruption at a major policy bank, and AbbVie sues an upstart drug maker
China Development Bank has become the target of the latest anti-corruption crackdown by China’s main graft buster. Will this affect China’s policy of lending big money to developing countries, and if so, what’s driving such a shift?
CHINA BULLETIN: No Fun for European Firms in China
In this week’s issue European businesses get glum on China, consumers write off June 18 shopping fest and a three-week stock rally crashes. On a scale of 1 to 100, we give the week a 40 for offshore-listed China stocks.
